Design of clinical trials for therapeutic cancer vaccines development.

[1]  A. Dalgleish,et al.  Improving the efficacy of cancer immunotherapy. , 2009, European journal of cancer.

[2]  B. Goldman,et al.  The cancer vaccine roller coaster , 2009, Nature Biotechnology.

[3]  O. Finn,et al.  Cancer vaccines: accomplishments and challenges. , 2008, Critical reviews in oncology/hematology.

[4]  M. Herlyn,et al.  Melanoma stem cells: the dark seed of melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Wicha,et al.  Cancer stem cells: a step toward the cure. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Atkins,et al.  Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments , 2008, Cancer.

[7]  E. Hersh,et al.  Phase 1 Trial of Intranodal Injection of a Melan-A/MART-1 DNA Plasmid Vaccine in Patients With Stage IV Melanoma , 2008, Journal of immunotherapy.

[8]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[9]  M. Frank,et al.  Cancer stem cells and human malignant melanoma , 2007, Pigment Cell & Melanoma Research.

[10]  A. Dalgleish,et al.  Cell based cancer vaccines: regulatory and commercial development. , 2007, Vaccine.

[11]  A. Mackiewicz,et al.  Clinical trials of active cancer immunotherapy , 2007, Expert opinion on investigational drugs.

[12]  J. Scheller,et al.  The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.

[13]  A. Eggermont,et al.  A clinical development paradigm for cancer vaccines and related biologics. , 2007, Journal of immunotherapy.

[14]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Purdie,et al.  Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma , 2006, Immunology and cell biology.

[16]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[17]  J. Schlom,et al.  Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. , 2006, Human gene therapy.

[18]  P. Srivastava,et al.  A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients , 2006, Cancer Immunology, Immunotherapy.

[19]  M. Hanna,et al.  Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. , 2005, Vaccine.

[20]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[21]  P. Chapman,et al.  Sequential Immunization of Melanoma Patients with GD3 Ganglioside Vaccine and Anti-Idiotypic Monoclonal Antibody That Mimics GD3 Ganglioside , 2004, Clinical Cancer Research.

[22]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[23]  V. Sondak,et al.  Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. , 2003, Seminars in cancer biology.

[24]  V. Sondak,et al.  Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma , 2003, Cancer.

[25]  S. Steinberg,et al.  Clinical trial designs for the early clinical development of therapeutic cancer vaccines. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Schirmacher,et al.  The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells , 2001, Oncogene.

[27]  P. Murawa,et al.  Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. , 2000, Immunology letters.

[28]  S. Groshen,et al.  Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[30]  P. Murawa,et al.  Immunogene Therapy of Human Melanoma , 1998 .

[31]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[32]  P. Murawa,et al.  Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. , 1995, Human gene therapy.

[33]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Heinrich,et al.  Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. , 1992, Journal of immunology.